Trump Executive Order Accelerates Regulatory Path for Psychedelic Therapies

President Donald Trump has signed an executive order designed to expedite the regulatory review process for psychedelic therapies targeting mental health conditions. The order focuses on reducing the time required for clinical trials and regulatory approvals, while simultaneously working to destigmatize these treatments among healthcare providers and patients. This federal signal is expected to shift investor sentiment, potentially bringing institutional capital into a sector previously viewed as high-risk. While the psychedelics market remains small, the shift in regulatory posture provides a catalyst for companies navigating the FDA's binary approval process, which mirrors traditional biotechnology development. Compass Pathways (CMPS) is positioned as a primary beneficiary due to its advanced development stage. The company's lead asset, COMP360, a synthetic psilocybin therapy for treatment-resistant depression, is currently in pivotal Phase 3 trials. Compass has already reported statistically significant and clinically meaningful data, demonstrating effects within one day and durability lasting at least six months for responding patients. Financially, Compass maintains a stronger liquidity position than many of its peers. As of the end of 2025, the company reported $149.6 million in cash and cash equivalents. With an annual cash burn estimated between $120 million and $145 million, management expects current funding to sustain operations into 2028, reducing the immediate need for dilutive financing. While the order provides a tailwind for other players such as Atai (ATAI) and Definium Therapeutics (DFTX), most of the sector remains in early-stage Phase 1 or 2 trials. The broader market impact will depend on whether the shortened timelines translate into faster FDA approvals and successful commercialization.